Skip to main content
Leonard Glass, MD, Endocrinology, Indianapolis, IN

LeonardCGlassMD

Endocrinology • Indianapolis, IN

Diabetes, Lipid Metabolism

Vice President Lilly Diabetes Global Medical Affairs

Join to view full profile

Dr. Glass is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Glass' full profile

Already have an account?

  • Office

    Lilly Corporate Ctr
    Indianapolis, IN 46285
    Phone+1 317-504-2375

Education & Training

  • University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of Medicine
    University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 1999 - 2003
  • University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of Medicine
    University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Internal Medicine, 1997 - 1999
  • Eastern Virginia Medical School
    Eastern Virginia Medical SchoolClass of 1997

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 1999 - 2026
  • IN State Medical License
    IN State Medical License 2005 - 2025
  • FL State Medical License
    FL State Medical License 2003 - 2005

Awards, Honors, & Recognition

  • Fellow (FACE) American Association of Clinical Endocrinology

Publications & Presentations

PubMed

Press Mentions

  • Zepbound Helps People Lose More Weight Than Wegovy, According to Eli Lilly Trial
    Zepbound Helps People Lose More Weight Than Wegovy, According to Eli Lilly TrialDecember 14th, 2024
  • Lilly’s Zepbound® (Tirzepatide) Superior to Wegovy® (Semaglutide) in Head-to-Head Trial Showing an Average Weight Loss of 20.2% vs. 13.7%
    Lilly’s Zepbound® (Tirzepatide) Superior to Wegovy® (Semaglutide) in Head-to-Head Trial Showing an Average Weight Loss of 20.2% vs. 13.7%December 5th, 2024
  • Zepbound Leads to More Weight Loss Than Wegovy, Says Drug Manufacturer Eli Lilly
    Zepbound Leads to More Weight Loss Than Wegovy, Says Drug Manufacturer Eli LillyDecember 5th, 2024
  • Join now to see all

Professional Memberships

Other Languages

  • Spanish

Dr. Leonard Glass, Dr. Leonard Glass, MD, Dr. L Glass, Dr. Leonard C Glass